Non-seminomatous Germ Cell Tumor
9
4
7
1
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
11.1%
1 terminated out of 9 trials
50.0%
-36.5% vs benchmark
11%
1 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (9)
Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
A Phase II Trial of Cabozantinib With Patients With Refractory GCTs
CD30 CAR for CD30+ NSGCT
Robot-assisted ICG-guided Sentinel Node Biopsy in Testicular Cancer
Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers
Validation of a Treatment Algorithm for Poor-Risk NSGCTnon Seminomatous Germ-cell Tumors
Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors
Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors